Wednesday, December 25, 2019 8:37:05 PM
One reason they gave for it was the price below $.01 would cause them to lose the OTC listing, that problem will be gone when we're above $.01 for ten days running, I believe we're getting close if it's not already happened.
With one patent coming through, and hopefully more in the future, I believe we'll continue to move up as long as the company advances into the clinic. Of course it's what happens in the clinic that determines what the patents are worth. If in fact the cream works on psoriasis and other skin diseases, I believe you could move the decimal point a couple places to the right, and then some.
If they get the patent for the sublingual tablet, and it permits multiple formulations administered in this way, I believe that it could become the preferred way to administer all sorts of cannabis formulations with none of the problems found with smoke, vape, etc.
Gary
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM